Fundraising FoxIndieBio — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Cellens develops a non-invasive, urine-based cancer diagnostics platform (Octosense) that uses nanoscale atomic-force imaging of single-cell biophysical markers combined with machine learning to detect cancer, with early data focused on bladder cancer detection.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Phuong (Jean) Pham(CEO)in
BoardDeborah Zajac(Director)inLena Chaihorsky-Hering(Director)Mohan Iyer(Director)inJesse Salk(Director)in
Co-investorsCancer FundCreative Destruction Lab (CDL)SOSV
iOrganBio builds CellForge, an AI- and automation-driven platform for engineering and manufacturing human cells and organoids.
Co-investorsCape Fear BioCapitalFirst Star VenturesHartmann CapitalSOSVAlix Ventures
Puna Bio develops microbial biostimulants, biofertilizers, and biofungicides for seed treatment based on extremophile bacteria collected from Argentina's Puna region, aimed at improving crop yields and regenerating degraded soils.
AgTechBiotechClimate TechSan Francisco, US
Carolina Belfiore(Executive Officer)inElisa Violeta Bertini(Executive Officer, Director)inFranco Martínez Levis(Executive Officer, Director)inMaría Eugenia Farías(Executive Officer)in
BoardDario Maffei(Director)Laurie Menoud(Director)in
Co-investorsAIR CapitalAt One VenturesCapria VenturesGLOCAL LatamGRIDXGrowth Science Ventures+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Finish Line Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.